Arming a replicating adenovirus with osteoprotegerin reduces the tumor burden in a murine model of osteolytic bone metastases of breast cancer

Cancer Gene Therapy

Volumn 17, Issue 12, 2010, Pages 893-905

  Cody, J J ^a   Rivera, A A ^b,g   Lyons, G R ^a,h   Yang, S W ^a   Wang, M ^b   Sarver, D B ^a,c   Wang, D ^c,d   Selander, K S ^e   Kuo, H C ^b   Meleth, S ^b   Feng, X ^a   Siegall, G P ^c,f   Douglas, J T ^b,f  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Mayo Clinic College of Medicine   (United States)

^e Heerskink School of Medicine   (United States)

^f UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h DUKE UNIVERSITY   (United States)

Author keywords

adenovirus; bone metastases; breast cancer; osteoprotegerin; virotherapy

Indexed keywords

ALPHA INTEGRIN; ARGININE; ASPARTIC ACID; CONDITIONALLY REPLICATING ADENOVIRUS; GLYCINE; IMMUNOGLOBULIN G1; OSTEOPROTEGERIN; RETINOBLASTOMA PROTEIN;

ADENOVIRUS 5; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CELL; COCULTURE; CONTROLLED STUDY; FEMALE; GENE DELETION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGAND BINDING; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; TUMOR VOLUME; VIRUS GENE; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; OSTEOPROTEGERIN; TUMOR BURDEN; VIRUS REPLICATION;

ADENOVIRIDAE; MURINAE;

EID: 78349307824     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.47     Document Type: Article

References (56)

1. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584-593.
2. Coleman RE. Management of bone metastases. Oncologist 2000; 5: 463-470.
3. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005: CD003474.
4. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18: 723-727.
5. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 2001; 8: 89-98.
6. Hermiston T. Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. J Clin Invest 2000; 105: 1169-1172.
7. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998; 19: 18-54.
8. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999; 140: 4451-4458.
9. Kakonen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 2003; 97: 834-839.
10. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319.
11. Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 2000; 141: 3478-3484.
12. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001; 61: 4432-4436.
13. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metas-tases. Cancer 2003; 97: 887-892.
14. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20: 345-357.
15. Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003; 63: 912-916.
16. Hawkins LK, Hermiston T. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region. Gene Ther 2001; 8: 1142-1148.
17. Tollefson AE, Scaria A, Hermiston TW, Ryerse JS, Wold LJ, Wold WS. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 1996; 70: 2296-2306.
18. Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001; 7: 120-126.
19. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19: 2-12.
20. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713.
21. Shayakhmetov DM, Li ZY, Ni S, Lieber A. Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res 2002; 62: 1063-1068.
22. Anders M, Hansen R, Ding RX, Rauen KA, Bissell MJ, Korn WM. Disruption of 3D tissue integrity facilitates adenovirus infection by deregulating the coxsackievirus and adenovirus receptor. Proc Natl Acad Sci USA 2003; 100: 1943-1948.
23. Harms JF, Welch DR, Samant RS, Shevde LA, Miele ME, Babu GR et al. A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin Exp Metastasis 2004; 21: 119-128.
24. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996; 98: 1544-1549.
25. Cowey S, Szafran AA, Kappes J, Zinn KR, Siegal GP, Desmond RA et al. Breast cancer metastasis to bone: evaluation of bioluminescent imaging and microSPECT/CT for detecting bone metastasis in immunodeficient mice. Clin Exp Metastasis 2007; 24: 389-401.
26. Suzuki K, Alemany R, Yamamoto M, Curiel DT. The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res 2002; 8: 3348-3359.
27. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273: 14363-14367.
28. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996; 70: 7498-7509.
29. Precious BaR, W C. Growth, purification and titration of adenoviruses. In: Mahy BWJ (ed). Virology: A Practical Approach. IRL: Oxford, 1985, pp. 193-205.
30. Kirby TO, Rivera A, Rein D, Wang M, Ulasov I, Breidenbach M et al. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res 2004; 10: 8697-8703.
31. Rivera AA, Wang M, Suzuki K, Uil TG, Krasnykh V, Curiel DT et al. Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo. Virology 2004; 320: 121-134.
32. Udagawa N, Takahashi N, Akatsu T, Sasaki T, Yamaguchi A, Kodama H et al. The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology 1989; 125: 1805-1813.
33. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Vaananen HK. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000; 15: 1337-1345.
34. Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM et al. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 2002; 52: 20-33.
35. Le LP, Le HN, Dmitriev IP, Davydova JG, Gavrikova T, Yamamoto S et al. Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling. J Natl Cancer Inst 2006; 98: 203-214.
36. Ono HA, Le LP, Davydova JG, Gavrikova T, Yamamoto M. Noninvasive visualization of adenovirus replication with a fluorescent reporter in the E3 region. Cancer Res 2005; 65: 10154-10158.
37. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987; 2: 595-610.
38. Rocconi RP, Zhu ZB, Stoff-Khalili M, Rivera AA, Lu B, Wang M et al. Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd). Gyne-col Oncol 2007; 105: 113-121.
39. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000; 6: 1134-1139.
40. Cody JJ, Douglas JT. Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther 2009; 16: 473-488.
41. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1: 571-573.
42. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C et al. Osteoprotegerin inhibits prostate cancer-induced osteoclas-togenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001; 107: 1235-1244.
43. Vanderkerken K, De Leenheer E, Shipman C, Asosingh K, Willems A, Van Camp B et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003; 63: 287-289.
44. Tannehill-Gregg SH, Levine AL, Nadella MV, Iguchi H, Rosol TJ. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Clin Exp Metastasis 2006; 23: 19-31.
45. Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 2008; 25: 119-129.
46. Zheng Y, Zhou H, Brennan K, Blair JM, Modzelewski JR, Seibel MJ et al. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 2007; 40: 471-478.
47. Miller RE, Roudier M, Jones J, Armstrong A, Canon J, Dougall WC. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther 2008; 7: 2160-2169.
48. Rae JM, Ramus SJ, Waltham M, Armes JE, Campbell IG, Clarke R et al. Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. Clin Exp Metastasis 2004; 21: 543-552.
49. Sellappan S, Grijalva R, Zhou X, Yang W, Eli MB, Mills GB et al. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res 2004; 64: 3479-3485.
50. Harms JF, Welch DR. MDA-MB-435 human breast carcinoma metastasis to bone. Clin Exp Metastasis 2003; 20: 327-334.
51. van der Pluijm G, Que I, Sijmons B, Buijs JT, Lowik CW, Wetterwald A et al. Interference with the microenviron-mental support impairs the de novo formation of bone metastases in vivo. Cancer Res 2005; 65: 7682-7690.
52. Fisher JL, Schmitt JF, Howard ML, Mackie PS, Choong PF, Risbridger GP. An in vivo model of prostate carcinoma growth and invasion in bone. Cell Tissue Res 2002; 307: 337-345.
53. Fisher JL, Mackie PS, Howard ML, Zhou H, Choong PF. The expression of the urokinase plasminogen activator system in metastatic murine osteosarcoma: an in vivo mouse model. Clin Cancer Res 2001; 7: 1654-1660.
54. Krasnykh VN, Douglas JT, van Beusechem VW. Genetic targeting of adenoviral vectors. Mol Ther 2000; 1: 391-405.
55. Kalyuzhniy O, Di Paolo NC, Silvestry M, Hofherr SE, Barry MA, Stewart PL et al. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci USA 2008; 105: 5483-5488.
56. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008; 132: 397-409.